129 results
P
ALL, NHL
I/C
CD22 CAR T-cells, CD19/CD22 CAR T-cells, anti-CD19 CAR T-cells
O
best complete response (bCR)
P
patients with de novo IAs
I/C
systematic review and meta-analysis of existing de novo IA cohorts, initial IAs in the middle cerebral artery
O
de novo IAs
P
sarcoma patients
I/C
Glasgow prognostic score (GPS) and C-reactive protein to albumin ratio (CAR), elevated GPS or CAR vs. non-elevated GPS or CAR
O
overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS)
P
idosos
I/C
prevenção de quedas, não-prevenção
O
prevenção de quedas
P
NAFLD, elderly, pre-LT type II diabetes mellitus
I/C
de novo PTMS, other liver diseases
O
cardiovascular disease events
P
pediatric and young adult population
I/C
CD19-specific CAR-T therapy
O
complete remission, relapse, adverse events, minimal residual negative complete remission
P
pacientes con COVID-19
I/C
inhibidores de la enzima convertidora de angiotensina, bloqueadores del receptor de angiotensina II, placebo o ningún tratamiento
O
efectos sobre la COVID-19
P
patients with de novo coronary artery lesions
I/C
drug-coated balloon (DCB) treatment, non-DCB devices (such as plain old balloon angioplasty (POBA), bare-metal stents (BMS), or drug-eluting stents (DES))
O
target lesion revascularization (TLR)
P
mujeres postmenopáusicas
I/C
uso de estrógenos
O
infección del tracto urinario sintomática
P
patients with large B cell lymphoma (LBCL)
I/C
bridging therapy (BT), CAR-T therapy
O
poorer overall survival, 1-year progression-free survival, complete response rate, and grade ≥3 immune effector cell-associated neurotoxicity syndrome